|国家科技期刊平台
首页|期刊导航|生物信息学|新型冠状病毒相关靶点小分子抑制剂虚拟筛选

新型冠状病毒相关靶点小分子抑制剂虚拟筛选OACSTPCD

Virtual screening of small molecular inhibitors for SARS-CoV-2 related targets

中文摘要英文摘要

为确定治疗新型冠状病毒(SARS-CoV-2)感染的候选药物,开展了针对SARS-CoV-2 的药物虚拟筛选研究.以SARS-CoV-2的刺突蛋白(S蛋白)和 3CL蛋白酶(主蛋白酶)作为药物靶点,以美国食品药品监督管理局(FDA)批准上市的 2 726 个小分子药物作为候选,通过分子对接方法,筛选出了 3 种(阿巴瑞克(Abarelix)、西曲瑞克(Cetrorelix)、鞣酸(Tannic acid))与S蛋白具有较强结合能力的小分子药物,1 种(戈舍瑞林(Goserelin))与 3CL蛋白酶具有较好结合能力的小分子药物,它们理论上都具有抑制新型冠状病毒复制的效果.将靶向3CL蛋白酶的候选药物与辉瑞公司开发的药物Paxlovid进行比较,发现其作用位点均集中于 3CL蛋白酶的第 130-200 位的残基周围,具有相似的结合位点与相互作用.此外也对候选药物的物理与化学性质及与基因相互作用进行了分析.本研究可为开发新型冠状病毒感染的治疗药物提供参考.

In order to identify drug candidates for the treatment of SARS-CoV-2 infection,a virtual screening of drugs against SARS-CoV-2 was conducted.Using Spike protein(S protein)and 3CL protease(Main protease)as targets and 2 726 small molecular drugs approved by the US Food and Drug Administration(FDA)as candidates for molecular docking,we screened three small molecule drugs(Abarelix,Cetrorelix and Tannic acid)with strong binding effect with S protein and one small molecule drug(Goserelin)with strong binding effect with 3CL protease,all of which have the ability to inhibit SARS-CoV-2 replication process theoretically.Drug candidates targeting 3CL protease were compared with Paxlovid developed by Pfizer Inc and each drug had similar binding sites and interactions near the 130th-200th residues of 3CL protease.In addition,the physical and chemical properties of drug candidates and their interactions with genes were analyzed.This research may provide a reference for the development of drugs for treatment of SARS-CoV-2 infection.

丁佳宁;刘宏德

东南大学 生物科学与医学工程学院,南京 210096

生物学

新型冠状病毒抑制剂分子对接虚拟筛选

SARS-CoV-2InhibitorMolecular dockingVirtual screening

《生物信息学》 2024 (001)

26-36 / 11

10.12113/202211003

评论